Your browser doesn't support javascript.
loading
Main issues in penetrating keratoplasty.
Alió, Jorge L; Niazi, Sana; Doroodgar, Farideh; Barrio, Jorge L Alió Del; Hashemi, Hassan; Javadi, Mohammad Ali.
Afiliação
  • Alió JL; Division of Ophthalmology, Universidad Miguel Hernández, Alicante, Spain.
  • Niazi S; Vissum Miranza Alicante, Alicante, Spain.
  • Doroodgar F; Translational Ophthalmology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Barrio JLAD; Negah Aref Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Hashemi H; Translational Ophthalmology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Javadi MA; Negah Aref Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Taiwan J Ophthalmol ; 14(1): 50-58, 2024.
Article em En | MEDLINE | ID: mdl-38654981
ABSTRACT
This review explores contemporary challenges in penetrating keratoplasty (PK), focusing on technical intricacies, technological advancements, and strategies for preventing graft rejection. A systematic literature search from January 2018 to July 2023 was conducted across PubMed, Cochrane, Web of Science, Scopus, and EMBASE. The inclusion criteria comprised studies on PK and its comparison with other corneal pathologies, with emphasis on keratoconus (KC). Two independent reviewers screened studies, extracting relevant data. The review covers PK evolution, highlighting infra-red femtosecond lasers' impact on graft shapes, minimizing astigmatism, and enhancing wound healing. Graft rejection, a primary complication, is examined, detailing risk factors and preventive measures. Preoperative considerations, diagnostic techniques for rejection, and PK in KC are discussed. Postoperative care's significance, including intraocular pressure monitoring and steroid administration, is emphasized. The paper concludes with a comprehensive approach to prevent graft rejection, involving topical and systemic medications. An outlook on evolving monoclonal antibody research is presented. As the field progresses, personalized approaches and ongoing therapeutic exploration are expected to refine strategies, enhancing PK outcomes.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article